Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > Concordia: long term investors to be rewarded
View:
Post by TOMMY1 on Jul 11, 2016 10:29am

Concordia: long term investors to be rewarded

This is a great article just out today on seekingalpha.com. Don't let the shorters get you down with this stock - CXR is a great long-term investment with short-term volitily.

Summary

Concordia share price has been under pressure due to industry-wide challenges, high leverage and Brexit concerns.

Under various scenarios, Concordia continues to deleverage with no medium-term risk of bankruptcy.

DCF and LBO analysis shows satisfactory returns and significant upside potential for CXR.

CXR sees limited near-term catalyst. Only strong results in the next couple quarters will restore investor confidence.

To invest in CXR, you need to have long-term investment horizon and believe in the stability of underlying cash flows.

Conclusion

Think of CXR as an LBO that is publicly traded. P/E firms might not want to invest because their normal maneuvers are already deployed in this case. There is no bankruptcy risk here, and deleveraging is still optimistic even under extremely conservative assumptions. IRR is satisfactory at ~20% even under conservative assumptions, with potential upside from pound strengthening and revenue growth. My analysis above assumes 65% margin at AMCo, even though management guided at 70%, which provides another important potential lever.

Risk factors for CXR includes any unpredictable changes to its market and product, including competitive landscape, that could severely harm the cash flows. It's premature to price in Brexit impact given it's early stage and underlying healthcare market is relatively sheltered from market swings. Pound movements are significant, but limited in its impact shown above in various sensitivities.

The missing piece in this analysis is that I am not an expert in the off-patent drug business and have limited visibility into CXR's product portfolios. This articles assess CXR purely from a financial perspective using simplified growth assumptions.

Bottom line is that if CXR maintains its normal course of business with moderate to none growth rate among its portfolio of drugs and pound sink further to 1.2 territory, time will reward those that establish a position early and hold 2-3 years, much like investing from a private equity perspective.

Concordia: An LBO That Trades Publicly?


Full article: https://seekingalpha.com/article/3987473-concordia-lbo-trades-publicly
Comment by sunshine7 on Jul 11, 2016 10:39am
what does it mean by: "P/E firms might not want to invest because their normal maneuvers are already deployed"?
Comment by TOMMY1 on Jul 11, 2016 11:06am
In the context of thinking of Concordia as a leveraged buyout (LBO), this has already been done. A LBO is "the acquisition of another company using a significant amount of borrowed money (bonds or loans) to meet the cost of acquisition.".
Comment by wordless on Jul 11, 2016 12:45pm
The only thing a P/E firm could do int his situation, is buyout Concordia and try to buy out all the expensive 7.5%-9% loans.  They could then layer it on with more reasonably priced debt. I don't know if this would be possible as I don't know the current terms of the debt in detail with respect to early retirement. Thaty said, I was never banking on a buyout.  But I do believe ...more  
Comment by MirrorWorldMan on Jul 11, 2016 1:53pm
Seeking Alpo pulp makes some nice points and their articles are widely read.  So it will help generate some US interest for the day.  Thinking longer term, the need to lower healthcare expenditure by 3rd party and government payers for the ageing baby boomers will generate an ideal climate for managed growth for companies who are willing to negotiate  formulary access for reduced ...more  
Comment by TOMMY1 on Jul 11, 2016 2:20pm
wordless - I agree, a cheeky bit of refinancing by a P/E firm to lower the high interest currently being paid would allow them to pay off the debt sooner, but the current terms might have some nasty penalties which may have put the interested P/E firms off. Negoiations may still be ongoing - who knows?!...but I'm not banking on it.   puma1 - great news about the decreased short ...more  
Comment by yycish1027 on Jul 11, 2016 3:02pm
Hi, tommy, Cindy asked the question during pastime earning call. I think it was on early debt repayment thing. Or I could be wrong. Not answered but they probably discussed offline. , I am on phone, format would be awkward. ///////// Cindy Guan- And do you have until the RP capacity limits on the debt tranches by end? Edward Borkowski- Sorry, can you just clarify, so you mean the early repurchase ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities